Risk factors and other epidemiologic considerations for cervical cancer screening: a narrative review for the U.S. Preventive Services Task Force
- PMID: 22006929
- DOI: 10.7326/0003-4819-155-10-201111150-00377
Risk factors and other epidemiologic considerations for cervical cancer screening: a narrative review for the U.S. Preventive Services Task Force
Abstract
Despite the success of cervical cancer screening programs, questions remain about the appropriate time to begin and end screening. This review explores epidemiologic and contextual data on cervical cancer screening to inform decisions about when screening should begin and end. Cervical cancer is rare among women younger than 20 years. Screening for cervical cancer in this age group is complicated by lower rates of detection and higher rates of false-positive results than in older women. Methods used to diagnose and treat cervical intraepithelial neoplasia have important potential adverse effects. High-risk human papillomavirus infections and abnormalities on cytologic and histologic examination have relatively high rates of regression. Accordingly, cervical cancer screening in women younger than 20 years may be harmful. The incidence of, and mortality rates from, cervical cancer and the proportion of U.S. women aged 65 years or older who have had a Papanicolaou smear within 3 years have decreased since 2000. Available evidence supports discontinuation of cervical cancer screening among women aged 65 years or older who have had adequate screening and are not otherwise at high risk. Further reductions in the burden of cervical cancer in older women are probably best achieved by focusing on screening those who have not been adequately screened.
Similar articles
-
Liquid-based cytology and human papillomavirus testing to screen for cervical cancer: a systematic review for the U.S. Preventive Services Task Force.Ann Intern Med. 2011 Nov 15;155(10):687-97, W214-5. doi: 10.7326/0003-4819-155-10-201111150-00376. Epub 2011 Oct 17. Ann Intern Med. 2011. PMID: 22006930 Review.
-
Design and methods of the evaluation of an HPV-based cervical cancer screening strategy in Mexico: The Morelos HPV Study.Salud Publica Mex. 2002 Jul-Aug;44(4):335-44. doi: 10.1590/s0036-36342002000400007. Salud Publica Mex. 2002. PMID: 12216521
-
Quality control of cervical cytology using a 3-type HPV mRNA test increases screening program sensitivity of cervical intraepithelial neoplasia grade 2+ in young Norwegian women-A cohort study.PLoS One. 2019 Nov 5;14(11):e0221546. doi: 10.1371/journal.pone.0221546. eCollection 2019. PLoS One. 2019. PMID: 31689301 Free PMC article.
-
Updated guidelines for papanicolaou tests, colposcopy, and human papillomavirus testing in adolescents.J Adolesc Health. 2008 Oct;43(4 Suppl):S41-51. doi: 10.1016/j.jadohealth.2008.04.007. Epub 2008 Jul 23. J Adolesc Health. 2008. PMID: 18809144 Free PMC article. Review.
-
[HPV test replaces Pap test in Uppsala].Lakartidningen. 2013 Mar 26-Apr 9;110(13-14):695-6. Lakartidningen. 2013. PMID: 23634626 Swedish. No abstract available.
Cited by
-
Non-use and inadequate use of cervical cancer screening among a representative sample of women in the United States.Front Public Health. 2024 Apr 22;12:1321253. doi: 10.3389/fpubh.2024.1321253. eCollection 2024. Front Public Health. 2024. PMID: 38711762 Free PMC article.
-
Cervical cancer incidence, mortality, and burden in China: a time-trend analysis and comparison with England and India based on the global burden of disease study 2019.Front Public Health. 2024 Mar 6;12:1358433. doi: 10.3389/fpubh.2024.1358433. eCollection 2024. Front Public Health. 2024. PMID: 38510348 Free PMC article.
-
Integrating primary care, shared decision making, and community engagement to facilitate equitable access to multi-cancer early detection clinical trials.Front Oncol. 2024 Feb 29;13:1307459. doi: 10.3389/fonc.2023.1307459. eCollection 2023. Front Oncol. 2024. PMID: 38486933 Free PMC article.
-
Spatial epidemiological analysis of the burden of liver cancer in China.Transl Cancer Res. 2024 Jan 31;13(1):363-370. doi: 10.21037/tcr-23-1240. Epub 2023 Dec 26. Transl Cancer Res. 2024. PMID: 38410220 Free PMC article.
-
Cancer prevalence, incidence, and mortality rates in Afghanistan in 2020: A review study.Cancer Rep (Hoboken). 2023 Sep;6(9):e1873. doi: 10.1002/cnr2.1873. Epub 2023 Aug 13. Cancer Rep (Hoboken). 2023. PMID: 37574721 Free PMC article. Review.